CN101969951B - 化合物在制备治疗关节炎的药物中的方法 - Google Patents

化合物在制备治疗关节炎的药物中的方法 Download PDF

Info

Publication number
CN101969951B
CN101969951B CN2008801242231A CN200880124223A CN101969951B CN 101969951 B CN101969951 B CN 101969951B CN 2008801242231 A CN2008801242231 A CN 2008801242231A CN 200880124223 A CN200880124223 A CN 200880124223A CN 101969951 B CN101969951 B CN 101969951B
Authority
CN
China
Prior art keywords
methyl
amino
benzoyl
piperazin
phenylthio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801242231A
Other languages
English (en)
Chinese (zh)
Other versions
CN101969951A (zh
Inventor
P·巴德威尔
T·加于尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
|abbvie|gong Si
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of CN101969951A publication Critical patent/CN101969951A/zh
Application granted granted Critical
Publication of CN101969951B publication Critical patent/CN101969951B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CN2008801242231A 2007-11-16 2008-11-14 化合物在制备治疗关节炎的药物中的方法 Expired - Fee Related CN101969951B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
US60/988,479 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Publications (2)

Publication Number Publication Date
CN101969951A CN101969951A (zh) 2011-02-09
CN101969951B true CN101969951B (zh) 2012-10-31

Family

ID=40291332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801242231A Expired - Fee Related CN101969951B (zh) 2007-11-16 2008-11-14 化合物在制备治疗关节炎的药物中的方法

Country Status (14)

Country Link
US (2) US20090176785A1 (https=)
EP (1) EP2231159A1 (https=)
JP (2) JP5450434B2 (https=)
KR (1) KR101585848B1 (https=)
CN (1) CN101969951B (https=)
AU (1) AU2008322595B2 (https=)
CA (1) CA2705294C (https=)
DO (1) DOP2013000169A (https=)
IL (2) IL205501A (https=)
MX (1) MX2010005395A (https=)
NZ (2) NZ601350A (https=)
RU (2) RU2472509C2 (https=)
WO (1) WO2009064938A1 (https=)
ZA (1) ZA201003434B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011119345A2 (en) * 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
TWI620736B (zh) 2010-11-23 2018-04-11 艾伯維巴哈馬有限公司 使用選擇性ｂｃｌ-２抑制劑之治療方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2018322059C1 (en) 2017-08-23 2024-09-12 Guangzhou Lupeng Pharmaceutical Company Ltd. BCL-2 inhibitors
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
MX2022005375A (es) 2019-11-05 2022-10-07 Abbvie Inc Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
KR20220158725A (ko) 2020-02-24 2022-12-01 광조우 루펭 파마슈티칼 컴퍼니 엘티디. Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체
WO2022140224A1 (en) 2020-12-22 2022-06-30 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965745A (en) * 1995-10-10 1999-10-12 Pfizer Inc Indole carbamates as leukotriene antagonists
WO2005049594A1 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
CN1867551A (zh) * 2003-09-03 2006-11-22 辉瑞大药厂 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP1265864A1 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
EP1888550B1 (en) * 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965745A (en) * 1995-10-10 1999-10-12 Pfizer Inc Indole carbamates as leukotriene antagonists
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
CN1867551A (zh) * 2003-09-03 2006-11-22 辉瑞大药厂 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物
WO2005049594A1 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
贾晓益等.白芍总苷对胶原性关节炎滑膜组织中Bcl22、Bax表达的影响.《安徽医科大学学报》.2006,第41卷(第2期),143-146. *

Also Published As

Publication number Publication date
KR101585848B1 (ko) 2016-01-15
AU2008322595A1 (en) 2009-05-22
MX2010005395A (es) 2010-06-02
IL205501A0 (en) 2010-12-30
JP2014065716A (ja) 2014-04-17
RU2010123796A (ru) 2011-12-27
CN101969951A (zh) 2011-02-09
WO2009064938A1 (en) 2009-05-22
RU2526201C2 (ru) 2014-08-20
AU2008322595B2 (en) 2014-01-30
JP5667684B2 (ja) 2015-02-12
NZ585085A (en) 2012-08-31
EP2231159A1 (en) 2010-09-29
RU2012143212A (ru) 2014-04-20
JP5450434B2 (ja) 2014-03-26
KR20100099172A (ko) 2010-09-10
RU2472509C2 (ru) 2013-01-20
IL205501A (en) 2013-08-29
DOP2013000169A (es) 2013-12-15
US20160101109A1 (en) 2016-04-14
WO2009064938A9 (en) 2009-08-06
US20090176785A1 (en) 2009-07-09
CA2705294A1 (en) 2009-05-22
JP2011503199A (ja) 2011-01-27
IL227641A0 (en) 2013-09-30
CA2705294C (en) 2016-05-17
NZ601350A (en) 2013-08-30
ZA201003434B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
CN101969951B (zh) 化合物在制备治疗关节炎的药物中的方法
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CA3002220C (en) Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AU2016204396B2 (en) Methods of treatment using selective Bcl-2 inhibitors
RU2481332C2 (ru) Октагидропенталеновые соединения в качестве антагонистов хемокиновых рецепторов
JP2005538099A5 (https=)
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CN101553224A (zh) 新型咪唑并噻唑和咪唑并唑
JP2010513283A (ja) 新規なオキサジアゾール化合物
RU2010153582A (ru) Новые трициклические соединения
RU2012127306A (ru) Новые трициклические соединения
US11512092B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN115068468B (zh) 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺
JP5882296B2 (ja) 創傷の予防及び治療のための組成物及び方法
RU2011111117A (ru) Лечение аутоиммунных заболеваний
HK40074977A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK40074982A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
WO2019217822A1 (en) Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
HK40011855B (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
JPWO2004063201A1 (ja) 統合失調症治療剤
NZ614347A (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130619

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130619

Address after: Illinois State

Patentee after: |ABBVIE|Gong Si

Address before: Illinois State

Patentee before: Abbott GmbH. & Co. Kg

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121031

Termination date: 20161114

CF01 Termination of patent right due to non-payment of annual fee